Steve Kafka joins Section 32 as managing partner; Takeda auctions off $660M drug portfolio in bid to reduce post-Shire M&A debt load
→ Former Thrive CEO and partner at Third Rock Ventures, Steve Kafka, has hopped aboard Section 32 as a managing partner. Within his new role, Kafka “will focus on supporting and expanding the firm’s investment portfolio and presence in Boston.” Currently, Kafka serves as the executive chairman at Thrive and at ArcherDX and he will continue to serve within these roles. Kafka’s previous stints include roles as president and COO at Foundation Medicine and serving in positions at Aileron Therapeutics, Infinity Pharmaceuticals, Millennium Pharmaceuticals, Strategic Decisions Group and Forrester Research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.